Growth Equity Opportunities Fund, Llc - Net Worth and Insider Trading

Growth Equity Opportunities Fund, Llc Net Worth

The estimated net worth of Growth Equity Opportunities Fund, Llc is at least $0 dollars as of 2024-12-01. Growth Equity Opportunities Fund, Llc is the 10% Owner of ARYx Therapeutics Inc and owns about 0 shares of ARYx Therapeutics Inc (ARYX) stock worth over $0. Details can be seen in Growth Equity Opportunities Fund, Llc's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Growth Equity Opportunities Fund, Llc has not made any transactions after 2011-03-10 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Growth Equity Opportunities Fund, Llc

Growth Equity Opportunities Fund, Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Growth Equity Opportunities Fund, Llc owns 3 companies in total, including Sunesis Pharmaceuticals Inc (SNSS) , ARYx Therapeutics Inc (ARYX) , and Viracta Therapeutics Inc (VIRX) .

Click here to see the complete history of Growth Equity Opportunities Fund, Llc’s form 4 insider trades.

Insider Ownership Summary of Growth Equity Opportunities Fund, Llc

Ticker	Comapny	Transaction Date	Type of Owner
SNSS	Sunesis Pharmaceuticals Inc	2014-08-27	10 percent owner
ARYX	ARYx Therapeutics Inc	2011-03-10	10 percent owner
VIRX	Viracta Therapeutics Inc	2009-04-03	10 percent owner

Growth Equity Opportunities Fund, Llc Latest Holdings Summary

Growth Equity Opportunities Fund, Llc currently owns a total of 1 stock. Growth Equity Opportunities Fund, Llc owns 0 shares of ARYx Therapeutics Inc (ARYX) as of March 10, 2011, with a value of $0.

Latest Holdings of Growth Equity Opportunities Fund, Llc

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ARYX	ARYx Therapeutics Inc	2011-03-10	0	0.00	0

Holding Weightings of Growth Equity Opportunities Fund, Llc

Growth Equity Opportunities Fund, Llc Form 4 Trading Tracker

According to the SEC Form 4 filings, Growth Equity Opportunities Fund, Llc has made a total of 0 transactions in ARYx Therapeutics Inc (ARYX) over the past 5 years. The most-recent trade in ARYx Therapeutics Inc is the sale of 4,469,274 shares on March 10, 2011, which brought Growth Equity Opportunities Fund, Llc around $312,849.

Insider Trading History of Growth Equity Opportunities Fund, Llc

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Growth Equity Opportunities Fund, Llc Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Growth Equity Opportunities Fund, Llc Ownership Network

Ownership Network List of Growth Equity Opportunities Fund, Llc

No Data

Ownership Network Relation of Growth Equity Opportunities Fund, Llc

Growth Equity Opportunities Fund, Llc Owned Company Details

What does Sunesis Pharmaceuticals Inc do?

Who are the key executives at Sunesis Pharmaceuticals Inc?

Growth Equity Opportunities Fund, Llc is the 10 percent owner of Sunesis Pharmaceuticals Inc. Other key executives at Sunesis Pharmaceuticals Inc include director & See Remarks Dayton Misfeldt , VP & Finance Tina Gullotta , and See Remarks Judith A. Fox .

Sunesis Pharmaceuticals Inc (SNSS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sunesis Pharmaceuticals Inc (SNSS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sunesis Pharmaceuticals Inc (SNSS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sunesis Pharmaceuticals Inc (SNSS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sunesis Pharmaceuticals Inc Insider Transactions

No Available Data

What does ARYx Therapeutics Inc do?

Who are the key executives at ARYx Therapeutics Inc?

Growth Equity Opportunities Fund, Llc is the 10 percent owner of ARYx Therapeutics Inc. Other key executives at ARYx Therapeutics Inc include 10 percent owner Mark W Perry , 10 percent owner Krishna Kittu Kolluri , and 10 percent owner Newhall Charles W Iii .

ARYx Therapeutics Inc (ARYX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of ARYx Therapeutics Inc (ARYX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ARYx Therapeutics Inc (ARYX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

ARYx Therapeutics Inc (ARYX)'s detailed insider trading history can be found in Insider Trading Tracker table.

ARYx Therapeutics Inc Insider Transactions

No Available Data

What does Viracta Therapeutics Inc do?

Who are the key executives at Viracta Therapeutics Inc?

Growth Equity Opportunities Fund, Llc is the 10 percent owner of Viracta Therapeutics Inc. Other key executives at Viracta Therapeutics Inc include Chief Executive Officer Daniel R. Chevallard , director & President and CEO Mark Rothera , and Chief Medical Officer Darrel P. Cohen .

Viracta Therapeutics Inc (VIRX) Insider Trades Summary

Over the past 18 months, Growth Equity Opportunities Fund, Llc made no insider transaction in Viracta Therapeutics Inc (VIRX). Other recent insider transactions involving Viracta Therapeutics Inc (VIRX) include a net sale of 10,637 shares made by Daniel R. Chevallard , and a net purchase of 100,000 shares made by Mark Rothera .

In summary, during the past 3 months, insiders sold 0 shares of Viracta Therapeutics Inc (VIRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 10,637 shares of Viracta Therapeutics Inc (VIRX) were sold and 100,000 shares were bought by its insiders, resulting in a net purchase of 89,363 shares.

Viracta Therapeutics Inc (VIRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Viracta Therapeutics Inc Insider Transactions

No Available Data

Growth Equity Opportunities Fund, Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Growth Equity Opportunities Fund, Llc. You might contact Growth Equity Opportunities Fund, Llc via mailing address: 1119 St. Paul Street, Baltimore Md 21202.

Discussions on Growth Equity Opportunities Fund, Llc

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.